Changes of inflammatory cytokines in patients with major depressive disorder before and after venlafaxine treatment
10.3760/cma.j.cn371468-20200212-01025
- VernacularTitle:重性抑郁障碍患者文拉法辛治疗前后炎性细胞因子的变化
- Author:
Liping CHEN
1
;
Jiyang PAN
Author Information
1. 广州市第一人民医院（华南理工大学附属第二医院）精神心理科 510180
- From:
Chinese Journal of Behavioral Medicine and Brain Science
2020;29(7):607-612
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the changes of serum hypersensitive C-reactive protein (hs-CRP), tumor necrosis factor levels of alpha (TNF-α) and interleukin-6(IL-6) in patients with major depressive disorder(MDD) before and after venlafaxine treatment.Methods:Thirty-five MDD patients (MDD group) and thirty ethnic origin, gender, age, BMI and education level matched healthy controls (HC group) were recruited.The 17-item Hamilton depression scale (HAMD-17), Young manic rating scale (YMRS) were used to evaluate mood changes and therapeutic effect.The level of serum hs-CRP was detected by immunoturbidimetry, and the contents of serum TNF-α and IL-6 were measured by Elisa.The changes of serum hs-CRP, TNF-α, IL-6 in MDD patients before and after monotherapy (venlafaxine) treatment for 8 weeks and the differences of inflammatory cytokines between the MDD group and HC group were analyzed by t test, and partial correlation analysis was used to analyze the relationship between the changes of inflammatory cytokines and clinical symptoms in patients before and after treatment. Results:Before treatment, there were no significant differences of serum hs-CRP, TNF-α and IL-6 between MDD group and HC group( P>0.05). After treatment for 8 weeks, the score of HAMD-17 in MDD group was significantly decreased compared with that in pretreatment((5.63±2.81), (22.49±4.48), t=14.40, P<0.01), however were still higher than that in HC group ((3.15±1.11), t=3.681, P<0.01). Serum levels of hs-CRP ((0.37±0.43)mg/L, (0.88±0.97)mg/L, t=3.097, P=0.006), TNF-α ((0.37±0.43)ng/L, (0.88±0.97)ng/L, t=3.097, P=0.006) and IL-6 ((4.70±2.30)ng/L, (6.47±4.07)ng/L, t=4.758, P<0.001) in post-treatment were significant lower than those in pretreatment for MDD patients.Serum level of hs-CRP ( t=-3.521, P<0.05), TNF-α ( t=-7.744, P<0.001) and IL-6( t=-3.337, P<0.05) in post-treatment MDD group were significantly lower than those in HC group.After controlling for age and BMI, partial correlation analysis showed that TNF-α level was negatively correlated with duration of disease in the MDD group before( r=-0.784, P=0.012) and after treatment( r=-0.658, P=0.020). Conclusion:Venlafaxine can reduce serum TNF-α, IL-6 and hs-CRP levels in patients with MDD, suggesting that changes in inflammatory cytokines may be involved in the mechanism of antidepressant therapy by venlafaxine.
